Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct-Dec;16(4):1220.
doi: 10.18549/PharmPract.2018.04.1220. Epub 2018 Dec 19.

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients

Lama Faddoul  1 , Bahia Chahine  2 , Sahar Haydar  3 , Sahar Abourida  4 , Souheil Hallit  5 , Etwal Bou Raad  6
Affiliations

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients

Lama Faddoul et al. Pharm Pract (Granada). 2018 Oct-Dec.

Abstract

Objective: The objective of this study is to compute the potential benefit of Pramipexole ER on total levodopa equivalent dose (LED) and Unified Parkinson Disease Rating Score (UPDRS-III) compared to mono- or combined therapy of pramipexole IR and/or carbidopa/levodopa.

Methods: This is a retrospective observational study conducted in a specialized PD (Parkinson Disease) and movement disease center in Lebanon between January and December 2017.

Results: A total of 176 patient's record was reviewed. Pramipexole ER showed a significant difference on the mean changes in LED and UPDRS-III score. After 13 weeks of initiating Pramipexole ER, the mean decrease in LED was -49.42 mg for all patients (p < 0.001, CI 95% [35.28-63.55]) and the mean decrease in UPDRS-III score for all patients was -6 points (P< 0.001).According to the subgroup analysis, patients aged 65 years and below, the change in mean total LED from baseline (350.80 mg) was a decrease of 63.19 mg with a p<0.001, CI 95% [42.07-84.31]. In patients aged more than 65 years and shifted to mono or combined pramipexole ER therapy, the change in mean total LED from baseline (559.25 mg) was a decrease of 34.67 mg with a p<0.001 CI 95% [16.16-53.18]. In addition the results showed that in patients having an UPDRS-III score of less than or equal to 33, the change in mean total LED from baseline (436.73 mg) was a decrease of 56.76 mg (p<0.001; CI 95% [41.32-72.20]). However, in patients having an UPDRS-III score of more than 33 the change in mean total LED from baseline (545.06 mg) was a decrease of 2.96 mg with a p value < 0.844 CI 95% [27.32-33.15].

Conclusions: This study demonstrated the efficacy of Pramipexole ER on decreasing the total levodopa equivalent dose (LED).The role of health care professionals is to maintain the patient on the lowest effective levodopa equivalent daily dose and optimize the treatment therapy, thus decreasing the side effects that might arise from overdosing of antiparkinsonian drugs.

Keywords: Antiparkinson Agents; Dose-Response Relationship; Drug; Lebanon; Levodopa; Parkinson Disease; Pramipexole; Retrospective Studies.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Change in levodopa equivalent dose.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Parkinson's Disease -- American Academy of Neurology. [(accessed February 26, 2018)];Patients.aan.com. Available at: http://patients.aan.com/disorders/?event=view&disorder_id=1029 .
    1. Seidl SE, Potashkin JA. The promise of neuroprotective agents in Parkinson's Disease. Front Neurol. 2011;2:68. doi: 10.3389/fneur.2011.00068. - DOI - PMC - PubMed
    1. Statistics by Country for Parkinson's Disease. [(accessed February 26, 2018)]; Available at: http://www.cureresearch.com/p/parkinsons_disease/stats-country_printer.htm .
    1. Parkinson Disease in Lebanon. [(accessed February 26, 2018)]; Available at: http://global-disease-burden.healthgrove.com/l/55401/Parkinson-Disease-i... .
    1. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683. doi: 10.1001/jama.2014.3654. - DOI - PubMed

LinkOut - more resources